| The companies are prohibited from engaging in the promotion of opioids or opioids products. The companies cannot provide financial rewards or impose discipline on employees based on the volume of opioids sold. The companies cannot manufacture, promote, or distribute any product containing more than 40 mg of oxycodone per pill and cannot in most circumstances offer discounts, coupons, or rebates for opioid products. Finally, the companies cannot provide funding or grants to third parties for the promotion of opioid products and cannot engage in any lobbying activity related to opioids. Seven of the eight companies (not Indivior) are also subject to suspicious order monitoring requirements similar to other opioid manufacturer settlements. Indivior is not included because the company primarily manufactures opioid use disorder treatments, not opioids, and has agreed not to manufacture or sell any opioid products for the next 10 years. This settlement brings Indiana to approximately $1.1 billion the total value of opioid settlements achieved since Attorney General Rokita took office in January of 2021. ### |
